Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Common psychiatric disorders (CPDs) and depression contribute significantly to the global epidemic of type 2 diabetes (T2D). We postulated a possible pathophysiological mechanism that through Bridge-Symptoms present in depression and CPDs, promotes the establishment of emotional eating, activation of the reward system, onset of overweight and obesity and, ultimately the increased risk of developing T2D. The plausibility of the proposed pathophysiological mechanism is supported by the mechanism of action of drugs such as naltrexone-bupropion currently approved for the treatment of both obesity/overweight with T2D and as separate active pharmaceutical ingredients in drug addiction, but also from initial evidence that is emerging regarding glucagon-like peptide 1 receptor agonists that appear to be effective in the treatment of drug addiction. We hope that our hypothesis may be useful in interpreting the higher prevalence of CPDs and depression in patients with T2D compared with the general population and may help refine the integrated psychiatric-diabetic therapy approach to improve the treatment and or remission of T2D.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229977 | PMC |
| http://dx.doi.org/10.4239/wjd.v15.i6.1374 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the predictive accuracy of cognitive screeners BAMCOG and MoCA in identifying postoperative delirium risk in aortic valve replacement patients: A cohort study.
PLOS Digit Health
September 2025
Department of Anesthesiology, Maastricht UMC+, Maastricht, The Netherlands.
Postoperative delirium (POD) and postoperative encephalopathy (POE) are common complications in older adults undergoing aortic valve replacement (AVR), yet the predictive accuracy of cognitive screening tools remains uncertain. In this prospective cohort study, 50 patients aged 65 years and older scheduled for AVR between January and October 2022 underwent preoperative assessment with the Brain Aging Monitor Cognitive Assessment (BAMCOG) and Montreal Cognitive Assessment (MoCA). Postoperatively, POD was evaluated with the Delirium Observation Screening (DOS) scale and POE with electroencephalography (EEG).
View Article and Find Full Text PDFAmbient Air Pollution and the Severity of Alzheimer Disease Neuropathology.
JAMA Neurol
September 2025
Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Importance: Exposure to fine particulate matter air pollution (PM2.5) may increase risk for dementia. It is unknown whether this association is mediated by dementia-related neuropathologic change found at autopsy.
View Article and Find Full Text PDFElinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment.
Neuropsychiatr Dis Treat
August 2025
Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA.
Brexpiprazole is a second-generation antipsychotic with multiple indications, including the treatment of schizophrenia. As a partial dopamine agonist, brexpiprazole differs from most other antipsychotics, yet uncertainties about its full mechanism of action have led to some ambiguity among prescribers. To address this gap, an international panel of psychiatric experts was organized and convened with funding from Otsuka Pharmaceutical Europe Ltd and H.
View Article and Find Full Text PDF